During the last session, ProKidney Corp (NASDAQ:PROK)’s traded shares were 0.39 million, with the beta value of the company hitting 1.31. At the end of the trading day, the stock’s price was $1.55, reflecting an intraday loss of -3.13% or -$0.05. The 52-week high for the PROK share is $4.44, that puts it down -186.45 from that peak though still a striking 27.74% gain since the share price plummeted to a 52-week low of $1.12. The company’s market capitalization is $449.00M, and the average intraday trading volume over the past 10 days was 0.27 million shares, and the average trade volume was 662.84K shares over the past three months.
ProKidney Corp (PROK) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 2.00. PROK has a Sell rating from 0 analyst(s) out of 6 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 5 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.15.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
ProKidney Corp (NASDAQ:PROK) trade information
ProKidney Corp (PROK) registered a -3.13% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -3.13% in intraday trading to $1.55, hitting a weekly high. The stock’s 5-day price performance is -11.43%, and it has moved by -0.32% in 30 days. Based on these gigs, the overall price performance for the year is -6.91%. The short interest in ProKidney Corp (NASDAQ:PROK) is 10.74 million shares and it means that shorts have 9.03 day(s) to cover.
The consensus price target of analysts on Wall Street is $5, which implies an increase of 69.0% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $3 and $6 respectively. As a result, PROK is trading at a discount of -287.1% off the target high and -93.55% off the low.
ProKidney Corp (PROK) estimates and forecasts
Statistics show that ProKidney Corp has underperformed its competitors in share price, compared to the industry in which it operates. ProKidney Corp (PROK) shares have gone down -29.55% during the last six months, with a year-to-date growth rate less than the industry average at 8.77% against 18.10. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to grow 16.70% this quarter and then drop -55.60% in the quarter after that.
While earnings are projected to return 12.21% in 2024.
PROK Dividends
ProKidney Corp is due to release its next quarterly earnings on 2024-Nov-10. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
ProKidney Corp (NASDAQ:PROK)’s Major holders
ProKidney Corp insiders own 27.85% of total outstanding shares while institutional holders control 39.43%, with the float percentage being 54.65%.
